

Program at A Glance

Thursday October 31, 2013

Time	Room	Program
08:00-18:00	-----	Registration

Friday November 1, 2013

Time	Room	Program
08:00-08:30	-----	Registration
08:30-09:00	Banquet Hall	Opening Ceremony
09:00-09:30		Kim Jim-Pok Lectureship
09:30-12:15		Plenary Session
12:30-13:30	Studio 1 & 2	Satellite Sessions (Beijing Union Pharmaceutical Factory)
	Hubin Hall	Satellite Sessions (TTY BIOPHARM Company Limited)
Concurrent Sessions		
13:30-17:30	Studio 6 & 8	Gastrointestinal Cancer
	Studio 1 & 2	Head and Neck Tumor
	Banquet Hall I	Hematology and Lymphoma
	Hubin Hall	Radiation Oncology
	Hujing Hall	Clinical Trial and Cancer Chemotherapy
	Banquet Hall II	Translational Medicine
18:00-20:00	Haihe Hall	Asia Pacific Cancer Control Leaders' Summit

Program at A Glance

Saturday November 2, 2013

Time	Room	Program
08:00-08:30	-----	Registration
Concurrent Sessions		
08:30- 12:00	Haihe Hall	Breast Cancer
	Hujing Hall	Lung Cancer
	Studio 6 & 8	Hepatobiliary cancer
	Studio 1 & 2	Biotherapy
	Hubin Hall	Interventional Therapy and Minimally Invasive Therapy
	Banquet Hall I	Gynecologic Cancer
	Banquet Hall II	Urological Cancer
12:00-13:30	Studio 3	APFOCC Executive Committee Meeting & APFOCC General Assembly
12:30-13:30	Haihe Hall	AstraZeneca Satellite Sessions (Breast Cancer Session)
	Hujing Hall	AstraZeneca Satellite Sessions (Lung Cancer Session)
Concurrent Sessions		
13:30-16:00	Haihe Hall	Breast Cancer
	Hujing Hall	Lung Cancer
	Studio 6 & 8	Pancreatic cancer
	Studio 1 & 2	Cancer Screening and Prevention
	Banquet Hall I	Oncology Nursing
	Banquet Hall II	Nutrition
	Banquet Hall III	Cancer Survivor
16:00-17:15	Haihe Hall	Plenary Session
17:15-18:00		Closing Ceremony & Young Investigator Award

Ancillary Meetings

Opening Ceremony

8:30 — 9:00, Friday, November 1, 2013, Banquet Hall, Tianjin Marriott Lakeview Hotel

Asia Pacific Cancer Control Leaders' Summit

18:00 — 20:00, Friday, November 1, 2013, Haihe Hall, Tianjin Marriott Lakeview Hotel

Theme:

Strategy of Cancer Control in Asian Pacific countries

Panel discussion:

Topic 1: Accelerate progress on cancer control in Asia Pacific countries

Topic 2: Reduce cancer burden in Asia Pacific countries

APFOCC Executive Committee Meeting

12:00 — 13:00, Saturday, November 2, 2013, Studio 3, Tianjin Marriott Lakeview Hotel

APFOCC General Assembly

13:00 — 13:30, Saturday, November 2, 2013, Studio 3, Tianjin Marriott Lakeview Hotel

Closing Ceremony

17:15 — 18:00, Saturday, November 2, 2013, Haihe Hall, Tianjin Marriott Lakeview Hotel

Plenary Session

9:00 — 12:15, Friday, November 1, 2013
Banquet Hall, Tianjin Marriott Lakeview Hotel

Kim Jim-Pok Lectureship

9:00-9:30

Clinical trials of new anticancer drugs developed in china in recent years



Yan Sun, M.D.
Member, Chinese Academy of Engineering, Director, National GCP Center for Anti-Cancer Agents China

9:30-9:55

Cancer in the world: the equity imperative



Mary Gospodarowicz, M.D.
President, Union for International Cancer Control (UICC) Princess Margaret Hospital, Canada

9:55-10:20

Guideline for the clinical practice of prostate cancer



Sien-Shih Chang, M.D.
Member, Chinese Academy of Engineering, National Yang-Ming University, Taiwan, China

10:35-11:00

National cancer planing



Cary Adams, M.B.A.
Chief Executive Officer, Union for International Cancer Control (UICC), Switzerland

11:00-11:25

Therapeutic targeting of deletion 5q MDS



Alan F. List, M.D.
President, H. Lee Moffitt Cancer Center, USA

11:25-11:50

Innovation and development of chemotherapy



Jacqueline Whang-Peng, M.D.
Academician, Council of Academia Sinica, Taiwan, China

11:50-12:15

A new generation of targeted anti-cancer therapies



Alex Matter, M.D.
Fellowship, Swiss Academy for Medical Science, CEO, Experimental Therapeutic Center, Singapore

16:00 — 17:15, Saturday, November 2, 2013

Haihe Hall, Tianjin Marriott Lakeview Hotel

16:00-16:25


Enhancing targeted therapy by understanding mechanisms of resistance



Webster Cavenee, Ph.D.
Director, Ludwig Institute for Cancer Research, San Diego Branch, USA

16:25-16:50

Global progress against cancer, challenges and opportunities



Margaret Foti, M.D.
Chief Executive Officer, American Association for Cancer Research, U.S.A.

16:50-17:15

Mechanisms of treatment-related symptoms in cancer patients



Charles S. Cleeland, M.D.
The University of Texas M. D. Anderson Cancer Center, USA

Concurrent Sessions

Gastrointestinal Cancer

13:30 — 17:30, Friday, November 1, 2013
Studio 6 & 8, Tianjin Marriott Lakeview Hotel

Part I: Gastric cancer section

Chairs: Lin Shen, Han Liang

13:35-14:00

Transformation of clinical excellence to patients' benefit through translational research in gastric cancer

Sung Hoon Noh

Yonsei University Health System, Yonsei University
College of Medicine, Korea

14:00-14:20

Comprehensive management of gastric cancer in China

Jiafu Ji

Peking University Cancer Hospital, China

14:20-14:35

An open, multicenter, phase II clinical trial to evaluate efficacy and safety of S-1 plus cisplatin in patients with advanced gastric cancer (AGC): HGCSG0702: preliminary report

Nobuyuki Ehira

Japanese Red Cross Kitami Hospital, Japan

14:35-14:50

Polymorphisms in the microRNA binding-site in the stem cell marker gene CD133 modify susceptibility to and survival of gastric cancer

Qiming Wang

Zhengzhou University Affiliated Cancer Hospital, China

14:50-15:05

Study on association of single nucleotide polymorphisms and chemotherapy sensitivity in advanced gastric cancer

Yuan Pan

Tianjin Medical University Cancer Institute and Hospital, China

15:05-15:20 Q & A

15:20-15:30 Tea Break

Part II: Colorectal cancer section

Chair: Suzhan Zhang

15:35-15:55

Current treatment of liver metastasis from colorectal cancer in Asia and NECTAR

Cathrine Teh

Manila Medical Center, Philippine

15:55-16:15

Clinical implications of genomic project on colorectal cancer

Maode Lai

China Pharmaceutical University, China

16:15-16:35

The treatment strategy of peritoneal carcinomatosis of gastric cancer patients in Korea Cancer Center Hospital

Jong Inn Lee

Korean Institute of Radiological and Medical Sciences, Korea

Concurrent Sessions

16:35-16:55

Treatment strategy and practice of liver metastasis from colorectal cancer

Peng Zhao

Tianjin Medical University Cancer Institute and Hospital, China

16:55-17:05

Laparoscopic versus open rectectomy for rectal cancer: a meta-analysis of results of randomized controlled trials on recurrence and mortality

Binghong Xiong

Chongqing Medical University, the First Affiliated Hospital, China

17:05-17:20 Q & A

17:20-17:30 Discussion

Head and Neck Tumor

13:30 — 17:30, Friday, November 1, 2013

Studio 1 & 2, Tianjin Marriott Lakeview Hotel

Part I

Chairs: Ming Gao, Zhiyuan Zhang

13:35-13:55

The challenges in addressing the West's fastest emerging cancer: HPV-related oropharyngeal carcinoma

Brian O'Sullivan

Princess Margaret Hospital, University of Toronto, Canada

13:55-14:15

Targeting key apoptosis regulators for new cancer therapeutics

Shaomeng Wang

University of Toronto, Canada

14:15-14:35

Epigenetic control of head and neck cancer metastasis

Cunyu Wang

UCLA, Los Angeles, CA, USA

14:35-14:55

Management of metastatic brain tumors

Changhun Rhee

Director General, Korea Cancer Center Hospital, Korea

14:55-15:15

Functional results of the partial laryngopharyngeal surgery

Liang Zhou

EENT Hospital of Fudan University, China

Concurrent Sessions

15:15-15:25 Q & A

15:25-15:30 Tea Break

Part II

Chairs: Guangyan Yu, Liang Zhou

15:35-15:55

How to train a head neck reconstruction surgeon?

Chenping Zhang

Shanghai Ninth People's Hospital Affiliated Shanghai
Jiao Tong University School of Medicine, China

15:55-16:15

Recent advance of molecular targeted therapy in
metastatic thyroid cancer

Ye Guo

Fudan University Shanghai Cancer Center, China

16:15-16:30

Mislocation and interaction of RET/GFR α 4/PSPN
are essential in the progression of human papillary
thyroid cancer

Bayarsaikhan Enkhjargal

National cancer center of Mongolia, Mongolia

16:30-16:45

NIS expression and highly aggressive PTC variants

Xiaolong Li

Tianjin Medical University Cancer Institute and
Hospital, China

16:45-17:00

Multifocality and total tumor diameter predict central
neck lymph node metastases in papillary thyroid
microcarcinoma

Qunzi Zhao

The 2nd Affiliated Hospital Zhejiang University School
of Medicine, China

17:00-17:15

TLR3 signaling promotes metastasis of papillary
thyroid cancer by modulating CD44 expression
through PI3K/Akt pathway

Dapeng Li

Wuhan Union Hospital, China

17:15-17:30 Q & A

Radiation Oncology

13:30 — 17:30, Friday, November 1, 2013
Hubin Hall, Tianjin Marriott Lakeview Hotel

Chairs: Xiaomao Guo, Shengli Ma, Luhua Wang

13:30-13:50

Stereotactic body radiotherapy treatment (SBRT)

Mohamed Ibrahim A Wahid

Pantai Hospital Kuala Lumpur, Malaysia

13:50-14:10

Emerging clinical applications in radiosurgery

John Adler

Stanford University Medical Center, USA

14:10-14:30

Stereotactic ablative radiotherapy for unresectable hepatocellular carcinoma patients who are unsuitable for or after failure of transarterial chemoembolization

Yeemin Jie

Tri-Service General Hospital, Taiwan, China

14:30-14:50

Treatment of nasopharyngeal carcinoma by TomoTherapy: five-year experience

Stephen Wan Leung

Yuan's General Hospital, Taiwan, China

14:50-15:10

Individualized radiotherapy: Development and Challenge

Jinming Yu

Shandong Cancer Hospital, China

15:10-15:30

Stereotactic body radiation therapy in early stage non-small cell lung cancer

Ping Wang

Tianjin Medical University Cancer Institute and Hospital, China

15:30-15:40 Tea Break

15:40-15:50

Study of the role of palliative radiotherapy in the management of incurable pediatric malignancies

Prashant Kumbhaj

SMS Medical College, India

15:50-16:00

The relationship between expression of NRAGE, HDAC3 and NF- κ B and radioresistance of esophageal squamous cell carcinoma

Yanling Yang

The Second Hospital of Hebei Medical University, China

16:00-16:10

Epigenetic regulation of bdnf gene transcription in irradiation-induced neurogenesis impairment and cognitive deficits

Shengjun Ji

The Second Affiliated Hospital of Soochow University, China

16:10-16:20

Research on regulative Cox-2 and radiosensitivity to esophageal cancer EC9706 cells

Hui Wu

Affiliated Tumor Hospital of Zhengzhou University, China

Concurrent Sessions

16:20-16:30

The clinical value of contouring clinical target volume for radiotherapy in locally advanced non-small cell lung cancer

Jiancheng Li

Fujian Provincial Tumor Hospital, China

16:30-16:40

Dose and volume factors to the acute radiation-induced heart disease

Jun Wang

The Fourth Hospital of Hebei Medical University, China

16:40-16:50

Animal study of sodium glycididazole to improve the effect of radiotherapy for recurrent esophageal carcinoma

Peipei Wu

Shandong Cancer Hospital and Institute, China

16:50-17:00

The role of radiotherapy in treating patients with primary malignant mediastinal non-seminomatous germ cell tumor: A 21-year experience at a single institution

Jianyang Wang

Cancer Hospital & Institute, Chinese Academy of Medical Sciences & Peking Union Medical College, China

17:00-17:10

Which is the optimal threshold for defining functional lung in SPECT lung perfusion imaging of lung cancer patients?

Xiuping Ding

Shandong Cancer Hospital and Institute, China

17:10-17:20

Comparative research on the efficacy of cyberknife® and surgical excision for stage I liver cancer

Zhiyong Yuan

Tianjin Medical University Cancer Institute and Hospital, China

17:20-17:30

Influence of blocking irradiation-induced autophagy by Chloroquine on radiosensitivity of esophageal cancer cells

Xiaoli Yuan

Sichuan Cancer Hospital, China

Hematology & Lymphoma

13:30 — 17:40, Friday, November 1, 2013
Banquet Hall I, Tianjin Marriott Lakeview Hotel

Part I: Invited speeches

Chairs: Wenqi Jiang, Jianxiang Wang, Jianyong Li, Huaqing Wang

13:35-14:00

The developing face of lymphoma genomics
Francesco Bertoni
Oncology Institute of Southern Switzerland,
Switzerland

14:00-14:25

Causes and consequences of microRNA dysregulation
in cancer
Carlo Croce
The Ohio State University, USA

14:25-14:50

Molecular diagnosis of lymphomas, from gene
expression to next generation sequencing
Timothy Greiner
University of Nebraska Medical Center, USA

14:50-15:15

Why Bortezomib cannot go with 'green'?
Li Jia
Centre for Haemato-Oncology Barts Cancer
Institute, University of London, UK

15:15-15:30

Recent advances in the diagnosis and treatment of
NK/T cell Lymphoma
Huiqiang Huang
Sun Yat-Sen University Cancer Center, China

15:30-15:45

Epigenetics in lymphoma: exploring novel diagnosis
biomarkers and therapeutic approaches
Xi Wang
Tianjin Medical University, China

15:45-15:55

Q & A

15:55-16:05

Tea Break

Part II: Free paper

*Chairs: Yizhuo Zhang, Daobin Zhou, Huiqiang
Huang, Lugui Qiu*

16:10-16:20

The function and pathogenesis of a novel fusion gene
TBLR1-RAR α in acute promyelocytic leukemia
Yirui Chen
Chinese Academy of Medical Sciences & Peking Union
Medical College, China

16:20-16:30

Expression of BAFF and BAFF-R in follicular
lymphoma: correlation with clinicopathologic
characteristics and survival outcomes
YaJun Li
Sun Yat-Sen University Cancer Center, China

16:30-16:40

BTK inhibitor PCI-32765 targets endogenous and
microenvironment-mediated B-cell receptor signaling
to suppress lymphoma cell growth and is highly
synergistic with Bortezomib against non-Hodgkin B-cell
lymphomas
Fulian Qu
Tianjin Medical University Cancer Institute and
Hospital, China

Concurrent Sessions

16:40-16:50

Transfection of chimeric anti-CD138 gene enhances natural killer cell line NK-92MI activation and killing of multiple myeloma cells

Hua Jiang

Myeloma & Lymphoma Center, Changzheng Hospital, The Second Military Medical University, China.

16:50-17:00

Outcomes of unrelated umbilical cord blood transplantation using a conditioning regimen of TBI/Ara-c/CY without ATG for adolescent and adults patients with high-risk hematologic malignancies

Zimin Sun

Anhui Provincial Hospital/Anhui Medical University, China

17:00-17:10

Characteristics of NOTCH1 mutation in adult T-cell acute lymphoblastic leukemia

Zheng Ge

The First Affiliated Hospital of Nanjing Medical University, China

17:10-17:20

Fast STR-PCR protocol enabling rapid and high quality chimerism analysis after allo-HSCT

Hongxing Liu

Ludaopei Hematology & Oncology Center, Hebei Yanda Hospital, China

17:20-17:30

The effect of containing ATG conditioning regimen on the relapse in adult patients with aggressive T cell lymphomas after allogeneic hematopoietic stem cell transplantation

Jun Yang

Shanghai Jiaotong University affiliated Shanghai First Peoples Hospital, China

17:30-17:40

Do patients with primary non-Hodgkin's lymphoma of female genital tract have high risk of CNS relapse?

Xinxin Cao

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China

Clinical Trail & Cancer Chemotherapy

13:30 — 17:30, Friday, November 1, 2013
Hujing Hall, Tianjin Marriott Lakeview Hotel

Part I

Chairs: Wenqi Jiang, Yi Ba

13:35-13:55

Anticancer drug clinical trials in China

Yuankai Shi

Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China

13:55-14:00 Q&A

14:00-14:20

Pharmaceutial R & D in China

Dayao Zhao

Janssen Pharmaceutical Research & Development, China

14:20-14:25 Q&A

14:25-14:45

Trends in anti-cancer drug research in China

Yinxiang Wang

Zhejiang Beta Pharma, Inc. (ZBPI), China

14:45-14:50 Q&A

15:00-15:07

Subsequent cancer risks of patients with epilepsy:a nation-wide epidemiological study from Sweden

Xinjun Li

Lund University, Sweden

15:08-15:14

The comparative analysis of preoperative stage and postoperative stage for esophageal carcinoma

Xue Qiao

Second Affiliated Hospital of Soochow University, China

15:15-15:20

Cetuximab in combination with chemoradiotherapy in Chinese patients with non-resectable, locally advanced esophageal squamous cell carcinoma: A prospective, multicenter phase II trail

Xue Meng

Shandong Cancer Hospital and Institute, Jinan, China

15:20-15:30 Tea Break

Part II

Chairs: Yuankai Shi, Kai Li

15:35-16:00

The role of molecular markers in guiding therapy for oligodendroglioma

Jan Buckner

Mayo Clinic, USA

16:00-16:05 Q&A

16:05-16:25

Early diagnosis and chemotherapy of gastric cancer

Yi Ba

Tianjin medical university cancer institute and hospital, China

16:25-16:30 Q&A

Concurrent Sessions

16:30-16:37

Clinical analysis of carcinoid: A report of 414 cases from a single centre

Yong Tang

Tianjin Medical University Cancer Institute and Hospital, China

16:37-16:44

Chidamide: A novel epigenetic therapy as an effective single agent treatment in patients with relapsed or refractory peripheral T-cell lymphoma

Yuankai Shi

Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China

16:44-16:51

Effects of Rifampin on the Pharmacokinetics of Lenvatinib in Healthy Subjects

Robert Shumaker

Eisai Inc., Woodcliff Lake, NJGA Thompson Consulting, Cincinnati, OH, USA

16:51-16:58

A novel CRM1 inhibitor targeting for NSCLC with EGFR-TKI resistance mutation

Shuai Wang

Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China

16:58-17:05

Generation and biological character analysis of EGFR-TKI resistant cell line

Xiaohong Han

Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China

17:05-17:13

A new biomarker heat shock protein 90 alpha as therapeutic monitor and predictor for lung cancer patients

Yuankai Shi

Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China

17:13-17:20

Phase I study of nimotuzumab combined with postoperative chemoradiotherapy in Chinese patients with malignant glioma

Wenbin Li, Jing Chen

Beijing Tiantan Hospital affiliated to Capital Medical University, China

17:20-17:30 Tea Break

Translational Medicine

13:30 — 17:30, Friday, November 1, 2013
Banquet Hall II, Tianjin Marriott Lakeview Hotel

Chairs: Qimin Zhan, Ning Zhang

13:35-13:55

Anti-tumor effects of Alarmins

Joost Oppenheim

Center for Cancer Research, National Cancer
Institute, USA

13:55-14:00 Q&A

14:00-14:20

Selective killing of oncogenic stem cells in cancer
chemoprevention

Lin Zhang

University of Pittsburgh Cancer Institute, USA

14:20-14:25 Q&A

14:25-14:45

Integrated genomics: impact on personalized cancer
medicine

Wei Zhang

University of Texas M.D. Anderson Cancer Center, USA

14:45-14:50 Q&A

14:50-15:10

Regenomics on intractable diseases: enhanced repair
of myocardial infarction via scaffold-supported
transepical delivery of resident cardiac stem
cells

Seungjin Lee

Ewha Womans University, Korea

15:10-15:15 Q&A

15:15-15:35

UHRF1 regulates Hedgehog signaling to in basal cell
carcinoma

Zhongjun Zhou

Department of Biochemistry, Li Ka Shing Faculty of
Medicine, The University of Hong Kong, China

15:35-15:40 Q&A

15:40-15:50 Tea Break

15:50-16:10

Dysregulated cell cycle regulators in tumorigenesis
and metastasis

Qimin Zhan

State Key Laboratory of Molecular Oncology, Cancer
Institute, Chinese Academy of Medical Sciences, China

16:10-16:15 Q&A

16:15-16:35

NIR triggered hematoporphyrin-based drug delivery
system for drug resistance reversal and ultra tumor
ablation

Ning Zhang

Tianjin Medical University, China

16:35-16:40 Q&A

16:40-17:00

Targeted delivery of PLK1-siRNA by ScFv suppresses
Her2+ breast cancer growth and metastasis

Erwei Song

Breast Tumor Center, Sun Yat-sen Memorial Hospital,
Sun Yat-sen University, Guangzhou, China

17:00-17:05 Q&A

Concurrent Sessions

17:05-17:25

MicroRNA-26a: a novel prognostic marker and
therapeutic target for HCC

Lunxiu Qin

Liver Cancer Institute & Zhongshan Hospital, Fudan
University, China

17:25-17:30 Q&A

Breast Cancer

8:30 — 16:00, Saturday, November 2, 2013

Haihe Hall, Tianjin Marriott Lakeview Hotel

8:30-8:40 Opening ceremony

Chair: Jin Zhang

Special guests: Shuling Li, Zhenzhou Shen, Jiaqing
Zhang

8:40-9:10

Invited keynote presentation

Chairs: Binghe Xu, Guosheng Ren

Trends and strategies of treatment of early stage breast
cancer

Zhimin Shao

Fudan University Cancer Hospital, China

Part I: Epidemiology and surgery

Chairs: Santai Song, Bin Zhang, Zhiyi Fang

9:10-9:30

Current trends of breast reconstruction after
mastectomy for breast cancer patients in China

Jiong Wu

Fudan University Cancer Hospital, China

9:30-9:50

Personalized breast cancer surgery in Seoul National
University Cancer Hospital

Dong Young Noh

Seoul National University Hospital, Korea

9:50-10:10

NKILA is an indispensable third wheel of the NFκB/
IκB complex in breast cancer cells

Erwei Song

Sun Yat-sen Memorial Hospital, China

Concurrent Sessions

10:10-10:40 Q & A

Chair: Da Pang

Expert Group: Xiang Wang, Shude Cui,
Hongyuan Li, Chengyu Luo, Qi Wang, Suisheng Yang,
Zhangjun Song

10:40-10:50 Tea Break

Part II: Targeting therapy

Chairs: Shenming Wang, Jun Jiang, Lin Gu

10:50-11:10

The chemical therapy progress of breast cancer

Binghe Xu

Cancer Institute&Hospital, Chinese Academy of
Medical Sciences, China

11:10-11:30

Single cell analysis of gene copy number changes in
breast cancer diagnostics

Anders Zetterberg

Karolinska Institute, Sweden

11:30-11:50

The management of patients with advanced breast
cancer

Zefei Jiang

Military Medical Academy Hospital, China

11:50-12:20 Q & A

Chair: Jinhai Tang

Expert Group: Qingyuan Zhang, Xiaojia Wang,
Jian Liu, Hong Zheng, Ling Jia, Qiang Zou,
Jianghua Ou

Part III: Endocrine therapy

Chairs: Mingtian Yang, Yongsheng Wang

12:20-12:40

Endocrine therapy in premenopausal breast cancer

Tao OuYang

Beijing Cancer Hospital, China

12:40-13:00

The endocrine therapy of advanced breast cancer

Ning Liao

Guangdong General Hospital, China

13:00-13:20 Q & A

Chair: Qiang Sun

Expert Group: Donggeng Liu, Xuening Duan,
Cuizhi Geng, Shui Wang, Hongjian Yang, Yali Cao,
Benzhong Wang

13:20-13:30 Tea Break

Part IV: Individualized and comprehensive therapy

Chairs: Fengxi Su, Yinhua Liu, Xuchen Cao

13:30-13:50

Deregulation of cancer energy hallmark during
tumorigenesis

Mong Hong Lee

M.D. Anderson Cancer Center, Houston USA

13:50-14:10

MRE11, a core protein of DNA double strand break
(DSB) repair protein in breast cancer

Mingfeng Hou

Kaohsiung Medical University Hospital, Kaohsiung,
Taiwan, China

Concurrent Sessions

14:10-14:30

Molecular typing and drug treatment of early breast cancer

Xichun Hu

Fudan University Cancer Hospital, China

14:30-14:50 Q & A

Chair: Zhongsheng Tong

Expert Group: Pin Zhang, Feng Jin, Zhimin Fan, Xi Wang, Jianjun He, Yu Wang, Dahua Mao

Part V : Diagnosis, radiotherapy and basic researches

Chairs: Kunwei Shen, Xiaoming Xie, Duo Ni

14:50-15:10

Would radiation dose-volume of cardiac structure has an impact on early cardiac toxicity in HER-2 positive breast cancer receiving concurrent trastuzumab and adjuvant radiotherapy?

Jiayi Chen

Fudan University Cancer Hospital, China

15:10-15:25

The treatment of patients with advanced breast cancer

Huiping Li

Beijing Cancer Hospital, China

15:25-15:40

Diagnosis of breast lesions with dynamic contrast-enhanced MR imaging, DWI, and ¹H MR spectroscopy

Peifang Liu

Tianjin Medical University Cancer Institute and Hospital, China

15:40-15:55

A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes

Peter A. Kaufman

Dartmouth-Hitchcock Medical Center Hematology/Oncology One Medical Center Drive Lebanon, USA

15:55-16:00

The summary speech of breast cancer Concurrent Session

Chairman: Jin Zhang

Lung Cancer

8:00 — 15:40, Saturday, November 2, 2013
Hujing Hall, Tianjin Marriott Lakeview Hotel

8:00-8:10
welcome and introduction (Changli Wang)

Part I: Surgical Treatment of Lung Cancer

Chairs: Qinghua Zhou, Qibin Song

08:10-08:30

Individualized surgical treatment for locally advanced non-small cell lung cancer based on molecular biomarkers

Qinghua Zhou

Tianjin Medical University General Hospital, China

08:30-08:50

Completely thoracoscopic lobectomy for lung cancer: China experience and initial results

Jun Wang

Peking university, People's hospital, China

08:50-09:05

Prognostic factors in resected non-small cell lung cancer

Dongsheng Yue

Tianjin Medical University Cancer Institute and Hospital, China

09:05-09:20

HOPX is methylated and exerts tumor suppressive function through Ras-induced senescence in human lung cancer

Yuan Chen

Institute of Pathology, University Hospital Jena, Friedrich Schiller University Jena, Germany

9:20-9:30 **Discussion**

9:30-9:40 **Tea Break**

Part II: Diagnosis and Test

Chairs: Shun Lu, Cheng Huang

09:40-10:00

Assessment of antiangiogenic agents in non-small cell lung cancer

Zhaoxiang Ye

Tianjin Medical University Cancer Institute and Hospital, China

10:00-10:20

Test of molecular marker for lung cancer

Terufumi KATO

Japan

10:20-10:40

EGFR and ALK gene testing in NSCLC

Xuan Zeng

Peking XieHe Hospital, Chinese academy of medical sciences, China

10:40-11:00

Liquid biopsy-based biomarker detection in small-cell lung cancer

Ying Cheng

Ji Lin Cancer hospital, China

11:00-11:20

Advances and significance of blood based whole genomic analysis for advanced lung cancer

Jie Wang

Peking university, Cancer hospital, China

Concurrent Sessions

11:20-11:40

Driven genes and translational research in lung cancer

Shun Lu

Shanghai Chest Hospital, China

11:40-11:55

Correlation between Cocksachievirus and lung cancer development

Zhongli Zhan

Tianjin Medical University Cancer Institute and Hospital, China

11:55-12:05 Discussion

12:05-13:10 Special speech

Part III: Development of Treatment and Research for Lung Cancer

Chairs: Kai Li, Baohui Han

13:30-13:50

Development of surgical treatment of non-small cell lung cancer

Heng Zhao

Shanghai Chest Hospital, China

13:50-14:10

Development of molecular targeted therapy for NSCLC in China

Yuankai Shi

Cancer Institute & Hospital, Chinese Academy of Medical Sciences, China

14:10-14:30

Development of second line treatment of NSCLC: Need to detect driven gene mutation status

Baohui Han

Shanghai Chest Hospital, China

14:30-14:50

Effect of postoperative 3D-conformal radiotherapy (3DCRT) for patients with p III A-N2 non-small-cell lung cancer (NSCLC) after complete resection and adjuvant chemotherapy: interim analysis of a prospective phase III study

Lvhua Wang

Cancer Hospital & Institute, Chinese Academy of Medical Sciences, China

14:50-15:10

JAK/STAT3 signaling is essential for TGF- β -induced epithelial -mesenchymal transition in lung cancer cells

Hongtao Zhang

Soochow University Laboratory of Cancer Molecular Genetics, medical College of Soochow University, Suzhou, China

15:10-15:30

MiR-26a enhances metastasis potential of lung cancer cells via AKT pathway by targeting PTEN

Ke Xu

Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, China

15:30-15:40 Discussion

15:40 adjourn

Hepatobiliary Cancer

8:30 — 11:45, Saturday, November 2, 2013
Studio 6 & 8, Tianjin Marriott Lakeview Hotel

Part I

Chairs: Jia Fan, Jiahong Dong

08:30-09:00

Research on molecular pathological mechanism of HCC.

Xinwei Wang

Center for Cancer Research National Cancer Institute, USA

09:00-09:30

Progresses in clinical therapy of liver cancer.

Qiang Li

Tianjin Medical University Cancer Institute&Hospital, China

9:30-9:45 Q & A

9:45-10:00 Tea Break

Part II

Chairs: Shenglong Ye, Jian Zhou

10:00-10:30

Perihilar liver resection for hilar cholangiocarcinoma.

Jiahong Dong

Chinese PLA General Hospital, China

10:30-11:00

Interpretation of the new TNM classification of biliary tract tumor.

Xiaoqing Jiang

Eastern Hepatobiliary Surgery Hospital; Institute of Oriental Hepatobiliary Surgery, China

11:00-11:30

Transcatheter arterial chemoembolization on liver cancer: current status and challenges.

Gaojun Teng

Zhongda Hospital Southeast University, China

11:30-11:45 Q & A

Concurrent Sessions

Biotherapy

8:30 — 11:55, Saturday, November 2, 2013
Studio 1 & 2, Tianjin Marriott Lakeview Hotel

Chairs: Bo Huang, Xiubao Ren

8:35-9:00

Cancer vaccines and immunotherapy: basic principles and translation to clinical trials

Jay Berzofsky

NCI, USA

9:00-9:25

Immune elements reshape cancer stemness and invasiveness

Weiping Zou

Michigan University, USA

9:25-9:50

Changing tumor microenvironment by local radiation and modified antibody

Yangxin Fu

University of Chicago, USA

9:50-10:15

Myeloid-derived suppressor cells in tumor immune escape

Qingqing Wang

Zhejiang University, China

10:15-10:35 Tea Break

10:35-11:00

Microparticles: a road to antitumor immunity

Bo Huang

Chinese Academy of Medical Sciences, China

11:00-11:25

HDAC inhibition promotes sustained tumor regression in the context of oncolytic immunotherapy

Yonghong Wan

McMaster University, Canada

11:25-11:40

Small GTPase RBJ mediates nuclear entrapment of MEK1/2 in tumor progression

Taoyong Chen

Second Military Medical University, China

11:40-11:55

Enhanced nasal mucosal delivery and immunogenicity of anti-caries DNA vaccine through incorporation of anionic liposomes in chitosan/DNA complexes

Xiangliang Yang

Huazhong University of Sciences and Technology, China

Interventional Therapy and Minimally Invasive Therapy

8:30 — 12:10, Saturday, November 2, 2013
Hubin Hall, Tianjin Marriott Lakeview Hotel

Part I

Chairs: Renjie Yang, Peihong Wu

8:30-8:50

Minimally invasive therapy and combination with other multi-subjects in oncology

Peihong Wu

Sun Yat-sen University Cancer Center, China

8:50-9:10

Palliative treatment of malignant trachea-bronchial stenosis with metallic stents

RenJie Yang

Beijing University Cancer Hospital, China

9:10-9:30

CT-guided percutaneous cryoablation of bone tumors

Yueyong Xiao

Chinese PLA General Hospital, Beijing, China

9:30-9:50

In vitro model to estimate the effects of ^{125}I seeds on cancer cells

Fujun Zhang

Sun Yat-sen University, Guangzhou, China

9:50-10:10

The PMWA of lung tumor

Weijun Fan

Sun Yat-sen University Cancer Center, China

10:10-10:30

Interventional treatment and target treatment of gastrointestinal tumors

Xu Zhu

Beijing University Cancer Hospital, Beijing, China

Part II

Chairs: Zhi Guo, Fujun Zhang

10:30-10:50

Radiofrequency ablation and radiofrequency ablation combined with TACE versus surgical resection for small hepatocellular carcinoma: a Meta-analysis

Chuansheng Zheng

Huazhong University of Science and Technology, China

10:50-11:10

Transarterial chemoembolization with gelatin sponge particles for hepatocellular carcinoma: safety and efficacy

Yuwei Zhang

Affiliated Zhongshan Hospital of Dalian University, China

11:10-11:30

The effect of cytotoxic activity of anticancer drugs on hepatocellular carcinoma cells in hypoxic-hyponutritional culture

Qiang Li

Beijing University Cancer Hospital, Beijing, China

11:30-11:50

A retrospective study of intervention treatment for 72 cases of gastric cancer with liver metastasis after failure venous chemotherapy

Peng Liu

Beijing University Cancer Hospital, Beijing, China

Concurrent Sessions

11:50-12:00

CT-guided percutaneous microwave ablation of adrenal malignant carcinoma

Xin Li

Sun Yat-sen University, China

12:00-12:10

Clinical therapeutic effect observation of arsenic trioxide combined transcatheter arterial chemoembolization in treating patients of primary liver cancer with pulmonary metastases

Hongtao Hu

Henan Cancer Hospital, China

Gynecologic Cancer

8:30 — 11:45, Saturday, November 2, 2013

Banquet Hall I, Tianjin Marriott Lakeview Hotel

08:30-09:00

The management of recurrent ovarian epithelial cancer: the approach of indication and contraindication for second cytoreductive surgery and choice for chemotherapeutic agents

Xiugui Sheng

Shandong Tumor hospital, China

09:00-09:35

Abdominal radical trachelectomy (ART) for cervical malignancies: surgical, oncological and fertility outcomes in 156 patients

Xiaohua Wu

Fudan University Shanghai Cancer Center, China

09:35-10:10

Rsf-1, a chromatin remodeling protein, interacts with cyclin E1 and promotes tumor development

Jim Jinn-Chyuan Sheu

China Medical University Taiwan, China

10:10-10:25 Tea Break

10:25-10:35

Evaluation of health utility in survivors of locally advanced cervical cancer

Soehartati Gondhowiardjo

University of Indonesia, Indonesia

10:35-10:45

Factors influencing uptake of cervical cancer screening among women in India: a pilot study

S. Badaya

M.B.B.S (Intern), Gajra Raja Medical College, Gwalior, India

10:45-10:55

Construction of CDK7 siRNA expression vector and effects on the cisplatin sensitivity of endometrial carcinoma cell

Wenxin Liu

Tianjin Medical University Cancer Institute and Hospital, China

10:55-11:05

Clinicopathological factors associated with para-aortic lymph node metastasis in endometrioid endometrial adenocarcinoma: a consecutive study of 689 Patients

Boer shan

Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, China

11:05-11:15

A prospective 212 case study of SLN biopsy for assessing the pelvic nodal status in early-stage cervical cancer

Dapeng Li

Shandong Tumor hospital, China

11:15-11:25

Rectal late side effects are determined by dose-volume parameters computed tomography image-guided brachytherapy for locally advanced cervical cancer of China

Yongchun Zhou

Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, China

11:25-11:35

Expression of Fli-1 was associated with the prognosis of endometrial cancer

Wei Song

Cancer center, The First Hospital, Jilin University, China

11:35-11:45 Q & A

Urological Cancer

8:25 — 11:40, Saturday, November 2, 2013

Banquet Hall II, Tianjin Marriott Lakeview Hotel

Part I

Chairs: Xin Yao, Changlin Li

8:25-8:30

Opening presentation

Yanqun Na

Peking University Shougang Hospital, China

8:30-9:00

Talk 1 Asian trend of primary androgen depletion therapy on the prostate cancer

Hideyuki Akaza

Department of Strategic investigation on comprehensive cancer network
Research Center for Advanced Science and Technology
The University of Tokyo, Japan

9:00-9:30

Oncocytic hybrid tumors associated with Birt-Hogg-Dubé (BHD) syndrome

Xming Yang

Department of Pathology, Northwestern University
Feinberg School of Medicine, Chicago, USA

9:30-10:00

Circulating tumor cells in kidney cancer

Minhan Tan

Institute of Bioengineering and Nanotechnology, Singapore

10:00-10:30

To be determined

Dingwei Ye

Fudan University Shanghai Cancer center, China

Concurrent Sessions

Part II

Chairs: Dingwei Ye, Ningchen Li

10:40-10:55

Optimal surgical margin in nephron-sparing surgery for T1b renal cell carcinoma

Xusheng Chen

Tianjin Medical University, Cancer Institute and Hospital, China

10:55-11:10

The effects of G250 promoter controlled conditionally replicative adenovirus expressing Ki67-siRNA on renal cancer cell in vitro

Jiacun Chen

Affiliated Hospital of Xuzhou Medical College, China

11:10-11:25

The prediction of extraprostatic extension in patients with clinically organ-confined prostate cancer

Qing Zhang

The Sixth Hospital of Shanghai Jiao Tong University, China

11:25-11:40

Preliminary study of the anti-tumor effect of human cord blood monocytes induced by mouse stromal cells for renal cell carcinoma

Jian Wang

Affiliated Hospital of Guangdong Medical College, China

Pancreatic Cancer

13:30 — 15:20, Saturday, November 2, 2013

Studio 6 & 8, Tianjin Marriott Lakeview Hotel

Chairs: Quanxing Ni, Jihui Hao

13:35-13:55

Molecular targeting treatment of pancreatic cancer

Min Li

The University of Texas Medical School at Houston, Houston, USA

13:55-14:15

Optimization of pancreaticojejunostomy in pancreaticoduodenectomy when treating resectable pancreatic cancer

Xianjun Yu

Fudan University Shanghai Cancer Center, Shanghai, China

14:15-14:25

A new approach for evaluating the resectability of pancreatic cancer

Huaizhi Wang

Southwest Hospital, Third Military Medical University, Chongqing, China

14:25-14:35

Characteristics of lymph node metastasis in pancreatic head cancer

Deliang Fu

Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China

14:35-14:45

Surgical approaches to pancreatic cancer

Mokenge Malafa

H. Lee Moffitt Cancer Center, Tampa, Florida, USA

Concurrent Sessions

14:45-14:55

The role of Hypoxia-inducible factor-1 α in pancreatic cancer

Jihui Hao

Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

14:55-15:10 Q & A

15:10-15:20 Tea Break

Nutrition

13:30 — 16:00, Saturday, November 2, 2013

Banquet Hall II, Tianjin Marriott Lakeview Hotel

Chair: Hanping Shi

13:30-14:00

Improving results of cancer therapies with clinical nutrition

Jonathan M. Asprer

University of Santo Tomas Hospital, Philippines

14:00-14:30

Effects of antioxidants of special nutrient VIUSID on oxidative stress

Eduardo Sanz

New York University & Catalysis S.A. Company, USA

14:30-15:00

Energy metabolism and normal nutritional demands

Wei Li

The First Affiliated Hospital, Jilin University, China

15:00-15:30

Nutrition therapy for patients with cachexia

Kang Yu

Peking Union Hospital, China

15:30-16:00

Current status and future development of cancer nutrition in China

Hanping Shi

The First Affiliated Hospital, Sun Yat-sen University, China

Concurrent Sessions

Prevention

13:30 — 16:00, Saturday, November 2, 2013
Studio 1 & 2, Tianjin Marriott Lakeview Hotel

Chair: Weicheng You

13:30-13:50

Global and local cancer control strategy in Asia

Kazuo Tajima

Mie University Hospital, Japan

13:50-14:10

Changing patterns of cancer incidence & treatment in Korea: How to improve cancer research & control

Jae Kyung Roh

Yonsei University College of Medicine, Korea

14:10-14:30

Association of tobacco smoking and body mass index with risk of total and cause-specific deaths in Asia

Wei Zheng

Vanderbilt University, USA

14:30-14:50

Impact of cancer prevention from molecular epidemiology

Daehee Kang

Seoul National University College of Medicine, Korea

14:50-15:10

Assessment of breast screening program in China

Kexin Chen

Tianjin University Cancer Hospital & Institute, China

15:10-15:30

Gastric cancer prevention by eradication of *H. pylori* at high-risk population in Linqu County, China

Weicheng You

Peking University Cancer Hospital & Institute, China

15:30-16:00 Q & A

Oncology Nursing

13:30 — 16:00, Saturday, November 2, 2013
Banquet Hall I, Tianjin Marriott Lakeview Hotel

Part I

Chairs: Bo Xu, Yongqin Jiang

13:35-14:05

Journey to oncology nursing excellence

Mary Gullatte

Oncology Nursing Society (ONS), USA

14:05-14:35

The importance and functions of evidence-based health care center

Peifen Mu

Yangming University, Taiwan, China

14:35-15:05

The influence of spirit nursing care model on social support and quality of life in elderly patients with tumors

Yongyi Chen

Hunan Tumor Hospital, China

Part II

Chairs: Yongyi Chen, Huiying Qin

15:05-15:20

The relationships between symptom distress and coping strategy in esophageal cancer patients undergoing postoperative adjuvant chemotherapy

Xiaodan Wu

Sun Yat-sen University Cancer Center, China

Concurrent Sessions

15:20-15:35

Investigation of sexuality and relative education received for currently treated cancer patients

Wanmin Qiang

Tianjin Medical University Cancer Hospital, China

15:35-15:50

The innovation and practice of oncology nursing in China

Bo Xu

Chinese Academy of Medical Science Cancer Hospital, China

15:50-16:00 Q & A

Cancer Survivor

13:00 — 15:00, Saturday, November 2, 2013

Banquet Hall III, Tianjin Marriott Lakeview Hotel

Part I: Patient Group Experience Change

13:00-13:05

Intro

Yin Qin

The Chinese Anti-Cancer Association

13:05-13:10

Welcome Note

Yin Wang

The Chinese Anti-Cancer Association

13:10-13:20

Patient Group Management

Anli Shi

The Chinese Anti-Cancer Association

13:20-13:30

Patient Education in Oncology

Xiuyi Zhi

The Chinese Anti-Cancer Association

13:30-13:40

Patient Group Experience Change Part 1

Delegate

CCRS-Neimeng Rehabilitation Group

13:40-13:50

Patient Group Experience Change Part 2

Delegate

CCRS- JiangSu Rehabilitation Group

Concurrent Sessions

13:50-14:00

Patient Group Experience Change Part 3

Zhengpin Yuan

CCRS- Shanghai Rehabilitation Group

14:55-15:00

Closing Note

Anli Shi

The Chinese Anti-Cancer Association

14:00-14:15

Tea Break

Part II: Patient Documentary Awarding Ceremony

14:15-14:20

Awarding Ceremongy Opening

Yin Qin

The Chinese Anti-Cancer Association

14:20-14:25

Awarding 'Best Producer'

Duanqi Liu

The Chinese Anti-Cancer Association

14:25-14:30

Awarding 'Best Director'

Yuankai Shi

The Chinese Anti-Cancer Association

14:30-14:35

Awarding 'Best Documentary Short'

Xiuyi Zhi

The Chinese Anti-Cancer Association

14:35-14:40

Awarding 'Best Leading Star'

Ying Wang, Anli Shi

The Chinese Anti-Cancer Association

14:40-14:55

Showcasing 'Best Documentary Short'